Kymera Therapeutics Inc at Bank of America Healthcare Conference Transcript
Good morning. Welcome to the third day of the Bank of America Healthcare Conference. My name is Geoff Meacham, I'm the Senior Biopharma Analyst here. And we're really excited today to have Kymera Therapeutics. Speaking on behalf of Kymera is the CEO, Nello Mainolfi. And we're going to do like a 5-minute or so presentation and then we'll do a Q&A afterwards. Nello?
Thanks, Geoff. Thanks for the invite and the opportunity to present. We just have a few slides of introduction, just to set the stage for the Q&A that we'll have in a few minutes. Just to remind everybody, Kymera was founded now almost 6 years ago with the goal of building a fully integrated biotech that will be able to take targeted protein degradation from an early technology into a commercial stage reality. The platform is obviously disease agnostic. The platform is also target type agnostic. We had decided early on to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
